Illumina (NASDAQ:ILMN) Buy Rating Has Been Reiterated Today By Stifel; The Price Objective Given is $215


Illumina (NASDAQ:ILMN) Rating Reaffirmed

They currently have a $215 target on Illumina (NASDAQ:ILMN). The target price by Stifel would suggest a potential upside of 18.17% from the company’s price per share. This has been revealed to investors in a very recent research note on Monday, 21 December.

From a total of 19 analysts covering Illumina Inc (NASDAQ:ILMN) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is $240 while the lowest target price is $133. The mean of all analyst targets is $183.13 with a 2.83% above today’s ($181.94) stock price. Illumina Inc was the topic of 22 analyst reports since July 22, 2015 according to the firm StockzIntelligence Inc. Piper Jaffray maintained shares on October 21 with “Overweight” rating. Leerink Swann downgraded shares to “Market Perform” rating and $185 target share price in a report from an October 1. Stifel Nicolaus maintained ILMN stock in a recent report from October 6 with “Buy” rating. BTIG Research maintained the rating on August 20. BTIG Research has a “Buy” rating and a $240 price target on shares. Finally, Cowen & Co maintained the stock with “Outperform” rating in a report issued on an October 2.

The stock increased 0.38% or $0.69 on December 18, striking $181.94. Approximately shares of stock traded hands. Illumina, Inc. (NASDAQ:ILMN) has declined 9.37% since May 18, 2015 and is downtrending. It has underperformed by 3.57% the S&P500.

The overall sentiment of institutions has decreased to 0.98 in Q2 2015. Its down 0.19, from 1.17 in 2015Q2. The ratio worsened, as 62 institutions have sold all the shares of Illumina, Inc. that they owned while 205 funds have taken shares off the table. 63 funds have purchased shares for the first time while 199 added to their positions. These institutions now hold 148.82 million shares or 7.94% more than the 137.87 million shares they owned in 2015Q2.

The Fund Bender Robert & Associates currently is holding shares equating to 7.54% of its total portfolio in Illumina, Inc. representing a total of 63,346 shares. Another fund,Messner & Smith Theme Value Investment Management Ltd Ca, is holding a total of 17,211 shares equating to 5.98% of their holdings. Additionally, Edgewood Management Llc has a 3.76 million share stake in Illumina, Inc. which represents 5.58% of their total portfolio. The Fund, Baillie Gifford & Co, based out of United Kingdom, has also built up a stake in the stock, which represents a total of 5.1% of their total portfolio. Finally Rosenblum Silverman Sutton S F Inc Ca, a fund which is based in the state of California reported a total holdings of 58,584 shares.

Insider activity is a very important aspect to track on any stock. Going back to February 26, 2015, shareholders of Illumina, Inc. have witnessed 0 buys, and a total of 42 insider sales equating to a net activity of approximately $62.93 million . Flatley Jay T sold 10,000 shares worth approximately $1.50M. Bradbury Daniel sold 1,700 shares worth approximately $247,878. Walt David R sold 2,000 shares worth approximately $343,294. Klausner Richard sold 423 shares worth approximately $73,264. The company insider Dadswell Charles sold 157 shares worth $27,192.

Illumina, Inc. is engaged in production development of sequencing-and array solutions for genetic analysis. The company has a market cap of $26.64 billion. The Firm offers integrated systems, consumables and analysis tools for genetic analysis. It has 53.1 P/E ratio. It also makes sequencing and array platforms, reagent kits and scanning equipment.

According to Zacks Investment Research, “Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company’s tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.”